vs
BYLINE BANCORP, INC.（BY）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是BYLINE BANCORP, INC.的2.0倍（$219.9M vs $112.4M），BYLINE BANCORP, INC.净利率更高（33.4% vs -1.0%，领先34.4%），BYLINE BANCORP, INC.同比增速更快（9.0% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 6.4%）
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
BY vs OFIX — 直观对比
营收规模更大
OFIX
是对方的2.0倍
$112.4M
营收增速更快
BY
高出7.1%
2.0%
净利率更高
BY
高出34.4%
-1.0%
两年增速更快
OFIX
近两年复合增速
6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.4M | $219.9M |
| 净利润 | $37.6M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 33.4% | -1.0% |
| 营收同比 | 9.0% | 2.0% |
| 净利润同比 | 33.0% | 92.4% |
| 每股收益（稀释后） | $0.83 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BYOFIX
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $219.9M | ||
| Q3 25 | $115.7M | $205.6M | ||
| Q2 25 | $110.5M | $203.1M | ||
| Q1 25 | $103.1M | $193.6M | ||
| Q4 24 | $104.7M | $215.7M | ||
| Q3 24 | $101.8M | $196.6M | ||
| Q2 24 | $99.4M | $198.6M |
净利润BYOFIX
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-2.2M | ||
| Q3 25 | $37.2M | $-22.8M | ||
| Q2 25 | $30.1M | $-14.1M | ||
| Q1 25 | $28.2M | $-53.1M | ||
| Q4 24 | $30.3M | $-29.1M | ||
| Q3 24 | $30.3M | $-27.4M | ||
| Q2 24 | $29.7M | $-33.4M |
毛利率BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 0.2% | ||
| Q3 25 | 43.1% | -8.3% | ||
| Q2 25 | 35.2% | -7.9% | ||
| Q1 25 | 36.4% | -25.2% | ||
| Q4 24 | 38.6% | -5.3% | ||
| Q3 24 | 39.3% | -9.6% | ||
| Q2 24 | 40.4% | -12.5% |
净利率BYOFIX
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -1.0% | ||
| Q3 25 | 32.1% | -11.1% | ||
| Q2 25 | 27.2% | -6.9% | ||
| Q1 25 | 27.4% | -27.4% | ||
| Q4 24 | 34.3% | -13.5% | ||
| Q3 24 | 29.8% | -13.9% | ||
| Q2 24 | 29.9% | -16.8% |
每股收益（稀释后）BYOFIX
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-0.05 | ||
| Q3 25 | $0.82 | $-0.57 | ||
| Q2 25 | $0.66 | $-0.36 | ||
| Q1 25 | $0.64 | $-1.35 | ||
| Q4 24 | $0.68 | $-0.76 | ||
| Q3 24 | $0.69 | $-0.71 | ||
| Q2 24 | $0.68 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.4M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $450.0M |
| 总资产 | $9.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BYOFIX
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $82.0M | ||
| Q3 25 | $259.0M | $62.9M | ||
| Q2 25 | $218.3M | $65.6M | ||
| Q1 25 | $421.3M | $58.0M | ||
| Q4 24 | $563.1M | $83.2M | ||
| Q3 24 | $452.6M | $30.1M | ||
| Q2 24 | $730.5M | $26.4M |
总债务BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益BYOFIX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $450.0M | ||
| Q3 25 | $1.2B | $442.5M | ||
| Q2 25 | $1.2B | $458.3M | ||
| Q1 25 | $1.1B | $458.3M | ||
| Q4 24 | $1.1B | $503.1M | ||
| Q3 24 | $1.1B | $525.9M | ||
| Q2 24 | $1.0B | $546.0M |
总资产BYOFIX
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $850.6M | ||
| Q3 25 | $9.8B | $832.6M | ||
| Q2 25 | $9.7B | $837.2M | ||
| Q1 25 | $9.6B | $823.1M | ||
| Q4 24 | $9.5B | $893.3M | ||
| Q3 24 | $9.4B | $867.9M | ||
| Q2 24 | $9.6B | $882.0M |
负债/权益比BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $27.7M | ||
| Q3 25 | $38.3M | $12.4M | ||
| Q2 25 | $16.3M | $11.6M | ||
| Q1 25 | $27.1M | $-18.4M | ||
| Q4 24 | $175.2M | $23.7M | ||
| Q3 24 | $19.8M | $11.7M | ||
| Q2 24 | $40.1M | $9.0M |
自由现金流BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $16.8M | ||
| Q3 25 | $38.0M | $2.5M | ||
| Q2 25 | $15.2M | $4.5M | ||
| Q1 25 | $25.0M | $-25.1M | ||
| Q4 24 | $171.2M | $15.2M | ||
| Q3 24 | $19.1M | $6.3M | ||
| Q2 24 | $39.4M | $-360.0K |
自由现金流率BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 7.6% | ||
| Q3 25 | 32.8% | 1.2% | ||
| Q2 25 | 13.7% | 2.2% | ||
| Q1 25 | 24.3% | -13.0% | ||
| Q4 24 | 163.5% | 7.0% | ||
| Q3 24 | 18.8% | 3.2% | ||
| Q2 24 | 39.7% | -0.2% |
资本支出强度BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 4.9% | ||
| Q3 25 | 0.3% | 4.8% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 2.0% | 3.5% | ||
| Q4 24 | 3.8% | 4.0% | ||
| Q3 24 | 0.6% | 2.7% | ||
| Q2 24 | 0.7% | 4.7% |
现金转化率BYOFIX
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BY
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
